Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein

Cancer Research

Volumn 72, Issue 22, 2012, Pages 5912-5920

  Arzumanyan, Alla ^a   Sambandam, Vaishnavi ^a   Clayton, Marcia M ^a   Choi, Steve S ^b,c   Xie, Guanhua ^b   Diehl, Anna Mae ^b   Yu, Dae Yeul ^d   Feitelson, Mark A ^a  

^a Temple University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HEPATITIS B VIRUS X PROTEIN; SONIC HEDGEHOG PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER LOCALIZATION; CELL GROWTH; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR PROMOTION; UPREGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; HEDGEHOG PROTEINS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSFECTION;

EID: 84869204689     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2329     Document Type: Article

References (48)

1. Feitelson MA. Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol 1999;181:188-202.
2. Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol 2011;46:974-90.
3. Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 2004;18:382-4.
4. Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM, et al. Epigenetic modi fication induced by hepatitis B virus X protein viainteraction with de novo DNA methyltransferase DNMT3A. J Hepatol 2009;50:377-87.
5. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432:324-31.
6. Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science 2004;304:1755-9.
7. Mimeault M, Batra S. Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 2010;62:497-524.
8. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009;9:873-86.
9. Kim HY, Cho HK, Hong SP, Cheong J. Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of GLI1 in liver cancer cells. Cancer Lett 2011;309:176-84.
10. Pereira TA, Witek RP, Syn WK, Choi SS, Bradrick S, Karaca GF, et al. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest 2010;90:1690-703.
11. Sicklick JK, Li YX, Melhem A, Schmelzer E, Zdanowicz M, Huang J, et al. Hedgehog signaling maintains resident hepatic progenitors throughout life. Am J Physiol Gastrointest Liver Physiol 2006;290:G859-70.
12. Omenetti A, Choi S, Michelotti G, Dehl AM. Hedgehog signaling in the liver. J Hepatol 2011;54:366-73.
13. Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006;27:1334-40.
14. Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation of CLI2 and CLI3 activities by an amino-terminal repression domain: implication of CLI2 and CLI3 as primary mediators of Shh signaling. Development 1999;126:3915-24.
15. Bai CB, Auerbach W, Lee JS, Stephen D, Joyner AL. Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development 2002;129:4753-61.
16. Ikram MS, Neill GW, Regl G, Eichberger T, Frischauf AM, Aberger F, et al. GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Invest Dermatol 2004;22:1503-9.
17. Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG. Selective down-regulation of CLI2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 2007;67:3583-93.
18. Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006;27:748-57.
19. Yu DY, Moon HB, Son JK, Jeong S, Yu SL, Yoon H, et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999;31:123-32.
20. Koo JS, Seong JK, Park C, Yu DY, Oh BK, Oh SH, et al. Large liver cell dysplasia in hepatitis B virus x transgenic mouse liver and human chronic hepatitis B virus-infected liver. Intervirology 2005;48:16-22.
21. Lian Z, Pan J, Liu J, Zhang S, Zhu M, Arbuthnot P, et al. The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene 1999;18:1677-87.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2(delta-delta) C(T) method. Methods 2001;25:402-8.
23. Fischer AH, Jacobson KA, Rose J, Zeller R. Paraffin embedding tissue samples for sectioning. CSH Protoc 2008;2008:pdb.prot4989.
24. Feitelson MA, Millman I, Duncan GD, Blumberg BS. Presence of antibodies to the polymerase gene product(s) of hepatitis B and woodchuck hepatitis virus in natural and experimental infections. J Med Virol 1988;24:121-36.
25. Arzumanyan A, Friedman T, Ng IO, Clayton M, Lian Z, Feitelson MA. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res 2011;71:3701-8.
26. Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, Kim YB, et al. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest 2008;118:1354-66.
27. De Smaele E, Ferretti E, Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010;11:707-18.
28. Liao X, Siu M, Au C, Wong E, Chan HY, Ip P, et al. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009;30:131-40.
29. Lara-Pezzi E, Gómez-Gaviro MV, Gálvez BG, Mira E, Iñiguez MA, Fresno M, et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing MMP-1 and COX-2 expression. J Clin Invest 2002;110:1831-8.
30. Wang W, London WT, Feitelson MA. HBxAg in HBV carrier patients with liver cancer. Cancer Res 1991;51:4971-7.
31. Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, et al. Histone deacetylase and Cullin3-REN (KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol 2010;12:132-42.
32. Arzumanyan A, Friedman T, Kotei E, Ng IO, Lian Z, Feitelson MA. Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 2012;31:563-72.
33. Dennler S, André J, Verrecchia F, Mauviel A. Cloning of the human CLI2 promoter: transcriptional activation by TGF-beta via SMAD3/beta-catenin cooperation. J Bio Chem 2009;284:31523-31.
34. Yoo YD, Ueda H, Park K, Flanders KC, Lee YI, Jay G, et al. Regulation of TGF-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest 1996;97:388-95.
35. Lee DK, Park SH, Yi Y, Choi SG, Lee C, Parks WT, et al. The hepatitis B virus encoded oncoprotein pX ampli fies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev 2001;15:455-66.
36. Ruiz i Altaba A, Mas C, Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007;17:438-47.
37. Su F, Schneider RJ. Hepatitis B virus HBx protein activates transcription factor NF-kappa B by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol 1996;70:4558-66.
38. Kasperczyk H, Baumann B, Debatin KM, Fulda S. Characterization of sonic hedgehog as a novel NF-kB target gene that promotes NF-κB-mediated apoptosis resistance and tumor growth in vivo. FASEB J 2009;23:21-33.
39. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH. Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One 2011;6:e16068.
40. Phillips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One 2011;6:e23943.
41. Dormoy V, Danilin S, Lindner V, Thomas L, Rothhut S, Coquard C, et al. The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. Mol Cancer 2009;8:123.
42. Ha HL, Shin HJ, Feitelson M, Yu DY. Oxidative stress and antioxidants in hepatitis B virus infected hepatic pathogenesis. World J Gastroenterol 2010;16:6035-43.
43. Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol 2011;46:289-96.
44. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A 2007;104:5895-900.
45. Riobó NA, Lu K, Ai X, Haines GM, Emerson CP. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci U S A 2006;103:4505-10.
46. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces MMP-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004;18:1123-5.
47. Tarn C, Lee S, Hu Y, Ashendel C, Andrisani OM. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 2001;276:34671-80.
48. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26.